Benjamin L Palleiko insider trades: KalVista Pharmaceuticals (KALV) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Benjamin reports to the SEC
Open-market buys and sales
37 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | KALV | ↓ Sell | 10,926 | $26.78 | $293K | Direct | May 26, 2026 (4d) |
| May 18, 2026 | KALV | ↓ Sell | 1,129 | $26.76 | $30K | Direct | May 19, 2026 (1d) |
| May 12, 2026 | KALV | ↓ Sell | 3,322 | $26.71 | $89K | Direct | May 13, 2026 (1d) |
| Mar 9, 2026 | KALV | ↓ Sell | 6,693 | $16.08 | $108K | Direct | Mar 10, 2026 (1d) |
| Feb 23, 2026 | KALV | ↓ Sell | 10,034 | $15.57 | $156K | Direct | Feb 24, 2026 (1d) |
| Feb 18, 2026 | KALV | ↓ Sell | 1,038 | $15.00 | $16K | Direct | Feb 19, 2026 (1d) |
| Dec 8, 2025 | KALV | ↓ Sell | 7,294 | $16.51 | $120K | Direct | Dec 9, 2025 (1d) |
| Nov 24, 2025 | KALV | ↓ Sell | 10,940 | $13.45 | $147K | Direct | Nov 26, 2025 (2d) |
| Nov 18, 2025 | KALV | ↓ Sell | 4,466 | $14.48 | $65K | Direct | Nov 19, 2025 (1d) |
| Nov 12, 2025 | KALV | ↓ Sell | 3,328 | $11.55 | $38K | Direct | Nov 13, 2025 (1d) |
| Sep 8, 2025 | KALV | ↓ Sell | 7,294 | $15.84 | $116K | Direct | Sep 9, 2025 (1d) |
| Aug 22, 2025 | KALV | ↓ Sell | 10,940 | $13.22 | $145K | Direct | Aug 25, 2025 (3d) |
| Aug 18, 2025 | KALV | ↓ Sell | 4,409 | $13.19 | $58K | Direct | Aug 19, 2025 (1d) |
| Jul 9, 2025 | KALV | ↓ Sell | 32,979 | $15.69 | $518K | Direct | Jul 10, 2025 (1d) |
| Jun 9, 2025 | KALV | ↓ Sell | 7,169 | $14.50 | $104K | Direct | Jun 10, 2025 (1d) |
| May 22, 2025 | KALV | ↓ Sell | 9,999 | $11.88 | $119K | Direct | May 23, 2025 (1d) |
| May 19, 2025 | KALV | ↓ Sell | 3,808 | $11.84 | $45K | Direct | May 20, 2025 (1d) |
| Mar 7, 2025 | KALV | ↓ Sell | 6,669 | $11.97 | $80K | Direct | Mar 10, 2025 (3d) |
| Feb 18, 2025 | KALV | ↓ Sell | 5,104 | $9.82 | $50K | Direct | Feb 19, 2025 (1d) |
| Dec 9, 2024 | KALV | ↓ Sell | 7,627 | $9.75 | $74K | Direct | Dec 9, 2024 (0d) |
| Nov 18, 2024 | KALV | ↓ Sell | 14,400 | $9.26 | $133K | Direct | Nov 19, 2024 (1d) |
| Sep 9, 2024 | KALV | ↓ Sell | 7,352 | $12.19 | $90K | Direct | Sep 10, 2024 (1d) |
| Aug 19, 2024 | KALV | ↓ Sell | 14,215 | $12.01 | $171K | Direct | Aug 21, 2024 (2d) |
| Jun 7, 2024 | KALV | ↓ Sell | 7,465 | $11.53 | $86K | Direct | Jun 10, 2024 (3d) |
| May 20, 2024 | KALV | ↓ Sell | 21,959 | $11.76 | $258K | Direct | May 21, 2024 (1d) |
| Feb 20, 2024 | KALV | ↓ Sell | 22,802 | $14.11 | $322K | Direct | Feb 21, 2024 (1d) |
| Feb 14, 2024 | KALV | ↓ Sell | 40,855 | $15.01 | $613K | Direct | Feb 16, 2024 (2d) |
| Nov 20, 2023 | KALV | ↓ Sell | 13,008 | $8.23 | $107K | Direct | Nov 21, 2023 (1d) |
| Aug 18, 2023 | KALV | ↓ Sell | 13,067 | $10.73 | $140K | Direct | Aug 21, 2023 (3d) |
| May 18, 2023 | KALV | ↓ Sell | 4,037 | $10.14 | $41K | Direct | May 19, 2023 (1d) |
| Feb 17, 2023 | KALV | ↓ Sell | 4,954 | $7.66 | $38K | Direct | Feb 23, 2023 (6d) |
| Nov 18, 2022 | KALV | ↓ Sell | 722 | $5.44 | $4K | Direct | Nov 21, 2022 (3d) |
| Aug 17, 2022 | KALV | ↓ Sell | 725 | $14.96 | $11K | Direct | Aug 19, 2022 (2d) |
| Feb 23, 2021 | KALV | ↓ Sell | 29,642 | $33.59 | $996K | Direct | Feb 25, 2021 (2d) |
| Dec 30, 2020 | KALV | ↓ Sell | 358 | $20.04 | $7K | Direct | Jan 4, 2021 (5d) |
| Apr 22, 2019 | KALV | ↓ Sell | 3,073 | $25.70 | $79K | Direct | Apr 22, 2019 (0d) |
| Sep 14, 2007 | PPCO | ↑ Buy | 1,500 | $10.87 | $16K | Direct | Sep 14, 2007 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KALV insiders
Open-market trades in the last 12 months
About Benjamin L Palleiko's insider trades
Benjamin L Palleiko is Chief Executive Officer at KalVista Pharmaceuticals (KALV). Since Sep 14, 2007, Benjamin has reported 1 open-market purchase worth $16K and 36 sales worth $5.5M on SEC Form 4. In the last 12 months: 10 sales ($1.1M).
Their filings also include option exercises (34 filings), grants and awards (25 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KALV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.